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Background: Activation of Rho, one of the small GTPases, and its major downstream target Rho-kinase (ROCK)
promotes the development and metastasis of cancer. We previously showed that elevation of Rho and ROCK
expression was associated with tumor invasion, metastasis, and an unfavorable prognosis in patients with
urothelial cancer of the bladder or upper urinary tract.
Methods: We investigated the effects of a ROCK inhibitor on the growth, migration, and apoptosis of bladder
cancer cells. We also examined phosphorylation of RhoA (RhoA activity) by measuring its GTP-bound active form
and assessed the expression of ROCK to explore the underlying molecular mechanisms.
Results: Lysophosphatidic acid (LPA) and geranylgeraniol (GGOH) induced an increase of cell proliferation and
migration in association with promotion of RhoA activity and upregulation of ROCK expression. The ROCK inhibitor
fasudil (HA-1077) suppressed cell proliferation and migration, and also induced apoptosis in a dose-dependent
manner. HA-1077 dramatically suppressed the expression of ROCK-I and ROCK-II, but did not affect RhoA activity.
Conclusions: These findings suggest that ROCK could be a potential molecular target for the treatment of
urothelial cancer.Background
The standard treatment for muscle-invasive bladder
cancer (MIBC) is radical cystectomy and bilateral pelvic
lymph node dissection (PLND), while that for upper
urinary tract cancer is radical nephroureterectomy and
retroperitoneal lymph node dissection (RPLND). These
radical procedures have become standard treatment
over the past 30 years, but patients still have a relatively
poor prognosis and the 5-year survival rate after surgery
is less than 50% [1-3]. Although systemic chemotherapy
with methotrexate, vinblastine, doxorubicin, and cisplatin
(M-VAC) can reduce the tumor burden in patients with
urothelial cancer, its influence on the prognosis is not very
impressive [4]. Gemcitabine plus cisplatin (GC) has a better* Correspondence: kamait@dokkyomed.ac.jp
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reproduction in any medium, provided the orsafety profile than M-VAC and may be considered as the
first-line treatment for metastatic bladder cancer [5]. Some
patients develop systemic metastases within a few years of
curative resection. The most frequent sites of metastasis are
the regional lymph nodes, liver, lungs, and bone [6], and
the outlook for these patients is poor. Presumably, re-
currence is due to occult micrometastasis at the time of
surgery occurring via the rich lymphatic drainage of the
bladder and upper urinary tract. Metastasis, i.e., tumor
cell spread from the primary lesion to a distant site [7],
is the major cause of cancer death. Various studies have
shown that poorly differentiated cancer, muscle invasion,
lymph node metastasis, and lymphovascular invasion are
associated with recurrence of bladder cancer and are un-
favorable prognostic factors. Therefore, it seems important
to investigate the process of tumor cell dissemination.
Tumor cell migration is essential for metastasis, and mi-
gration involves rearrangement of the actin cytoskeleton.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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skeletal proteins could be important for understanding
tumor metastasis. Members of the Rho family of small
GTPases are involved in regulating a variety of cellular
processes, including organization of the microfilament
network, intercellular contact, and malignant transform-
ation [8]. These cellular events are all interrelated. Specif-
ically, certain subfamilies of Rho proteins are involved in
regulating the actin cytoskeleton during the formation of
stress fibers and focal adhesions within cells. The Rac
subfamily regulates the formation of lamellipodia and
membrane ruffles, while the Cdc42 subfamily regulates
filopodia. Both lamellipodia and filopodia are seen at
the advancing edge of motile cells, while retraction occurs
on the opposite side [9,10], and these processes are ac-
companied by reorganization of the actin cytoskeleton.
Rho-associated serine-threonine protein kinase (ROCK)
[11,12] is one of the best characterized downstream ef-
fectors of Rho. ROCK is activated when it selectively
binds to the active GTP-bound form of Rho, after which
activated ROCK interacts with the actin cytoskeleton to
promote stress fiber formation and the assembly of focal
contacts [13,14].
GTPases from the Rho family have been linked to
progression of human cancer, and the Rho/ROCK path-
way is considered to be involved in tumor progression
by regulating the actin cytoskeleton [15-17]. In fact,
(R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexane-
carboxamide dihydrochloride (Y-27632) [18] is a specific
ROCK inhibitor that suppresses tumor growth and metas-
tasis, indicating that the Rho/ROCK pathway may be a
good target for preventing tumor invasion and metastasis
[19,20]. Thus, this pathway is an attractive molecular tar-
get for anticancer therapy. We previously reported that
overexpression of Rho and ROCK proteins by bladder
cancer and upper urinary tract cancer was associated with
poorly differentiated histology, muscle invasion, lymph
node metastasis, and shorter survival, indicating that the
Rho/ROCK pathway is involved in the progression of
urothelial cancer [21-23]. Accordingly, suppression of
the Rho/ROCK pathway might potentially improve the
outcome of patients with urothelial cancer.
Fasudil (HA-1077) was developed as a pharmacological
ROCK inhibitor [24,25]. HA-1077 and its major active
metabolite after oral administration (hydroxyfasudil) po-
tently inhibit ROCK by promoting myosin light chain
phosphorylation in vascular smooth muscle cells [26,27].
It has been reported that HA-1077 is effective for the
treatment of cardiovascular disease, including coronary and
cerebral vasospasm, arteriosclerosis/stenosis, ischemia/
reperfusion injury, systemic hypertension, pulmonary
hypertension, stroke, and heart failure [25]. Among the
various ROCK inhibitors, HA1077 is the only clinically
available one without obvious adverse effects [28]. HA-1077has been recognized as a promising agent for preventing
recurrent vasospasm of cerebral arteries after aneurysmal
subarachnoid hemorrhage and its use is covered by the
Japanese national health insurance system.
Because it inhibits the Rho/ROCK pathway, we inves-
tigated whether HA-1077 could block the proliferation
and migration of bladder cancer cell lines or induce
apoptosis of these cells. Our objective was to assess the
value of the Rho/ROCK pathway as a molecular target
for anticancer therapy. In this report, we discuss the
clinical potential of HA-1077 for use in targeted cancer
therapy.Methods
Cell culture
Two human bladder cancer cell lines (5637 and UM-
UC-3) were obtained from the American Type Culture
Collection (ATCC, Rockville, MD). Cells were grown
in RPMI-1640 medium supplemented with fetal bovine
serum, 2 mM L-glutamine, 100 mg/mL streptomycin,
and 100 units/mL penicillin (all from Life Technologies,
Carlsbad, CA). Culture was performed at 37°C in a hu-
midified atmosphere with 5% CO2. Adherent cells were
detached from the culture dishes with trypsin/EDTA
(Sigma, Deisenhofen, Germany).Inhibition of cell growth
5637 cells and UM-UC-3 cells (5 × 104/well) were
seeded into 96-well plates in serum-containing medium
and were allowed to attach for 24 h. Then the medium
was removed and replaced with new medium containing
various concentrations of HA-1077. After being cultured
for 72 h, the cells were incubated with 50 μL of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT, 5 mg/mL; Sigma, St Louis, USA) for 1 h at 37.8°C.
The formazan product was dissolved in 100 mL of DMSO
and its absorbance was measured at a wavelength of
630 nm in a microplate reader. Proliferation of 5637
cells and UM-UC-3 cells was also assessed by quantita-
tive ELISA based on the incorporation of BrdU during
DNA synthesis (Roche Diagnostics, Mannheim, Germany),
which was performed as reported previously [29]. The
in vitro antiproliferative effect of HA-1077 was evaluated
after incubation of cells in the presence of HA-1077 with
or without lysophosphatidic acid (LPA) and geranylgera-
niol (GGOH), which is an intermediate of the mevalonate
pathway. Results were expressed as the ratio of the
number of viable cells after incubation with HA-1077
to the number of cells in control cultures with PBS (a
value of 100% was assigned to control cultures after incu-
bation for 72 h). HA-1077 was kindly donated by Asahi
Kasei Pharma (Tokyo, Japan). Each experiment was
repeated five times.
Abe et al. BMC Cancer 2014, 14:412 Page 3 of 12
http://www.biomedcentral.com/1471-2407/14/412Clonogenic assay
Cells (100 cells/well) were seeded in 6-well plate. After
cells adhered, HA-1077 (30 μM) or same volume of
DMSO were added into medium. The medium and che-
micals were freshly changed every two days. The cells
were cultured for 8 days and stained with 6% glutaralde-
hyde and 0.5% crystal violet, as described previously
[30,31]. Each experiment was repeated three times.
Induction of apoptosis
Induction of apoptosis in bladder cancer cell lines by
HA-1077 with or without LPA and GGOH was evalu-
ated after incubation of 1 × 105 cells for 24 hours in
serum-free medium, followed by exchange of the medium
for 10% FBS containing HA-1077 at its IC50 concentra-
tion. Cells were harvested by centrifugation and incubated
for 24 hours at 4°C in 10 × fetal bovine serum. Then
quantification of DNA fragmentation was done with an
Apoptosis in situ Detection Kit (Wako Pure Chemical
Industries, Osaka, Japan), and the average percentage
was calculated for the three areas with the highest num-
ber of apoptotic cells among 500 cells in a single field
at × 200 magnification. Apoptotic cells were identified
by the terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate biotin nick end-labeling (TUNEL)
method using an in situ apoptosis detection Guava
TUNEL kit (Merck Millipore, Darmstadt, Germany) [32].
Each experiment was repeated five times.
Migration assay
The migration assay was performed using a modified
Boyden chamber with a 24-well dish. Filters with 8-μm
pores (Nucleopore Corp., Pleasanton, CA) were coated
with Matrigel (40 mg; Collaborative Biomedical, Becton
Dickinson Labware, San Jose, CA). Cells (2.5 × 104) and
were placed into 100 ml of complete RPMI medium in
the upper chamber, while the lower chamber was filled
with 1 mL of RPM1 medium containing LPA, GGOH,
HA-1077, or BSA. After incubation for 48 hours, cells
were fixed in methanol for 15 min and then stained with
0.05% crystal violet in PBS for 15 min. Cells on the upper
side of each filter were removed with cotton swabs, and
the filters were washed in PBS. Then the cells on the
underside of each filter were counted under a microscope
(type 090–135.001, Leica Microsystems, Wetzlar, Germany).
The ratio of migrated cells to viable cells at control cells
were set as 1.0 and the ratio of migrated cells to viable
cells at treated cells were calculated as a percentage of the
control. Clones were plated in triplicate for each experi-
ment, and each experiment was repeated five times.
RhoA activation assay and Western blotting
To measure the phosphorylated active RhoA (RhoA
activity; i.e., its GTP-bound active form), we performed aRho-binding domain (RBD) affinity precipitation assay
for RhoA-GTP with a specific antibody targeting RhoA
according to the manufacturer’s protocol (Cytoskeleton,
BK036, Denver, CO) [23,33]. Active RhoA was precipi-
tated from cell lysates (200 mg) with 15 mg of GST-RED
(containing amino acids −8-89 of Rhotekin), which was
expressed in Escherichia coli and bound to agarose
beads. The precipitates were washed with washing
buffer (50 mmol/L Tris [pH 7.2], 150 mmol/L NaCl,
10 mmol/L MgCl2, 0.1 mmol/L phenylmethylsulfonyl
fluoride, 10 mg/mL aprotinin, and 10 mg/mL leupeptin).
After adding the loading buffer and boiling for 5 min, the
bound proteins were resolved on 12% polyacrylamide gel,
transferred to a nitrocellulose membrane, and immuno-
blotted with the anti-RhoA antibody. After washing the
pellet three times, the bound proteins were analyzed by
Western blotting, as described previously. Briefly, proteins
from total cell lysate (75 mg) or proteins obtained by
trichloroacetic acid precipitation of conditioned medium
harvested after 48 h of incubation (when the cells reached
confluence) were separated by SDS-PAGE, followed by
electrotransfer to a polyvinylidene difluoride membrane
(Immobilon-P membrane; Millipore, Bedford, MA). After
the membrane was blocked in a solution of 5% skim milk,
0.1% Tween 20, and PBS, the bound proteins were probed
with primary antibodies directed against RhoA and β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA). Hela cells
were used as the positive control as described previously
[23]. Then the membranes were washed and incubated
with horseradish peroxidase-conjugated secondary anti-
bodies for 60 min. Antibody-bound protein bands were
detected with enhanced chemiluminescence reagents
(Amersham Pharmacia Biotech, Piscataway, NJ) and photo-
graphed with Kodak X-Omat Blue autoradiography film
(Perkin Elmer Life Science, Boston, MA). In contrast
to RhoA, we could not obtain commercial antibodies
for phosphorylated active ROCK. Instead, we examined
ROCK-I and ROCK-II protein expression using specific
antibodies (sc-6055 for ROCK-I and sc-1851 for ROCK-II,
each diluted 1:2000; Santa Cruz Biotechnology, Santa
Cruz, CA). Bands of antibody-bound proteins were visual-
ized by chemiluminescence, densitometry of the blotted
membrane was done with a PDI imaging scanner (Agfa
Japan, Tokyo), and the data were analyzed with NIH
Image software. Expression of phosphorylated RhoA,
ROCK-I, and ROCK-II was calculated relative to that
of β-actin (set at 1.0) by densitometric analysis, as described
previously [21,23,34,35]. Each experiment was repeated
five times.
Immunohistochemistry
Immunohistochemistry was done using the same specific
antibodies as those for Western blotting, in order to sup-
port the data obtained by Western blotting as described
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ROCK-I, and ROCK-II in the culture supernatants
from the HA1077-treated bladder cancer cell lines and
the control (non-treated bladder cancer cell lines) were
measured. For each sample, 4 randomly selected areas
were observed under high magnification and 100
tumor cells in each area were counted to calculate the
proportion of positive cells.
Statistical analysis
Data were analyzed by the Mann–Whitney U test for
comparisons between two groups [21,23,35]. Because
Boneferroni’s correction is generally employed for multiple
comparisons, the Mann–Whitney U test was corrected by
this method. In all analyses, a P value of less than 0.05 was
considered significant. Data were analyzed with commer-
cially available software.
Results
Cell proliferation was inhibited by HA-1077 in a dose-
dependent manner (Figure 1).
In clonogenic assay, HA-1077 made significantly less num-
ber of colonies compared to control cultures (Figure 1B).
On immunohistochemical analysis, the cytosolic com-
partment showed brown staining in most of the cancer
cells, indicating high RhoA activity and high ROCK-I and
ROCK-II protein levels, while the nuclei showed very
weak staining (Figure 2). This staining pattern was identicalFigure 1 The inhibitory effects of HA-1077 on cell proliferation. Cell p
assay (B), HA-1077 significantly decreased the number of colonies compareto that detected in our previous study [21-23]. 70-80% of
the cells from both bladder cancer cell lines showed mod-
erate to strong cytoplasmic staining by anti-RhoA anti-
body, and weak to moderate cytoplasmic staining by
anti-ROCK-I and anti-ROCK-II antibodies. HA-1077
reduced the level of reactivity with anti-ROCK-I and
anti-ROCK-II antibodies to very weak staining in 20-30%
of tumor cells, while the extent of staining for anti-RhoA
antibody was not changed much, but its intensity was re-
duced to weak or moderate.
Western blotting revealed that LPA and GGOH in-
creased RhoA activity, as well as the expression of
ROCK-I and ROCK-II (Figure 3). HA-1077 dramatically
decreased the expression of ROCK-I and ROCK-II, and
this decrease was not reversed by addition of LPA and
GGOH. In contrast, HA-1077 did not reduce RhoA activ-
ity, while LPA and GGOH increased RhoA activity despite
the addition of HA-1077.Inhibition of cell proliferation by HA-1077
We examined the inhibitory effect of HA-1077 on the
in vitro growth of human bladder cancer cell lines.
Addition of LPA and GGOH increased cell prolifera-
tion along with upregulation of RhoA activity and ele-
vation of expression of ROCK-I and ROCK-II (Figures 4
and 5). Cell proliferation was inhibited by HA-1077 in a
dose-dependent manner, both when HA-1077 was added
alone and when it was added in combination with LPAroliferation was inhibited by HA-1077 in 5637 cell (A). In clonogenic
d with control cultures in 5637 cells.
Figure 2 Immunohistochemical staining using anti-RhoA, anti-ROCK-I and anti-ROCK-II monoclonal antibodies in 5637 (x20 magnification).
70-80% of tumor cells showed moderate to strong cytoplasmic staining reaction for anti-RhoA antibody, and weak to moderate cytoplasmic staining
for anti-ROCK-I and anti-ROCK-II antibodies. HA-1077 reduced the staining reactivity for anti-ROCK-I and anti-ROCK-II antibodies to very weak staining in
only 20-30% of tumor cells, while it did not decrease the staining for anti-RhoA antibody with weak to moderate staining.
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and ROCK-II was significantly decreased by HA-1077 in a
dose-dependent manner, but RhoA activity was only
reduced slightly (Figures 4B-D, and 5B-D).
On the other hand, comparison between cells treated
by HA-1077 alone and those treated by HA-1077 inFigure 3 Representative bands identified by Western blotting in 5637
ROCK-II (164 kDa), and beta-actin (42 kDa). Hela cells were used as the pos
of RhoA activity, ROCK-I and ROCK-II. While HA-1077 significantly decreased
not blocked by addition of LPA plus GGOH. HA-1077 did not influence Rhocombination with LPA and GGOH revealed that RhoA
activity was higher in the latter cells at each HA-1077
concentration (Figures 4B and 5B), while the difference
in the expression of ROCK-I and ROCK-II gradually
became smaller at higher HA-1077 concentrations
(Figures 4C,D and 5C,D).and UM-UC-3 cells. Expression of RhoA (24 kDa), ROCK-I (160 kDa),
itive control. In both cancer cells, LPA plus GGOH induced upregulation
ROCK-I and ROCK-II expression, this inhibitory effect of HA-1077 was
A activity.
Figure 4 Inhibiting effect of HA-1077 on proliferation and RhoA activity and ROCK expression in 5637 cell using the 3-(4,5-dimethyl-2-
thiazolyl)-2,5diphenyl-2H-tetrazolium (MTT) assay. The ratio of the cells treated with various doses (0.5–30 μM) of HA-1077 to control cells
(HA-1077 0 μM) set as 1.0 were calculated. HA-1077 inhibited the growth of these cells in a dose-dependent manner (A). HA-1077 did not reduce
the RhoA activity (B), but suppressed ROCK-I (C) and ROCK-II (D) in dose-dependent manner. The data show the 95% confidential interval.
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We examined the effect of HA-1077 on apoptosis of
human bladder cancer cells in vitro. Addition of HA-1077
to cultured cells led to marked induction of apoptosis in a
dose-dependent manner compared with control cultures,
and this effect was seen for both HA-1077 alone and
HA-1077 combined with LPA and GGOH (Figures 6A, B).
When the difference in the percentage of apoptotic cells
at each HA-1077 concentration was compared between
cultures with HA-1077 alone and cultures with HA-1077
plus LPA and GGOH, it gradually decreased at higher
concentrations of HA-1077 (Figures 6C, D).
Influence of HA-1077 on LPA-induced cell migration
We next examined the effect of HA-1077 on the migra-
tion of cultured human bladder cancer cells. Addition of
LPA and GGOH increased the migration of bladder can-
cer cells compared with control cultures (Figures 7A
and 8A). Cell migration was suppressed by HA-1077 ina dose-dependent manner, both in cultures with HA-1077
alone and in cultures with HA-1077 plus LPA and GGOH
(Figures 7A and 8A). At the same time, RhoA activity and
the expression of ROCK-I and ROCK-II were all signifi-
cantly reduced by HA-1077 in a dose-dependent manner
(Figures 7B-D and B-D). The dose-dependent down-
regulation of the expression of these proteins by HA-1077
is likely to occur in parallel to the reduction in the number
of migrating cells. Regarding changes of protein expres-
sion, the difference of ROCK-I and ROCK-II expression
between cultures with HA-1077 alone and cultures with
HA-1077 plus LPA and GGOH gradually decreased at
higher concentrations of HA-1077 (Figures 7C, D and
8C, D). In contrast, RhoA activity was higher in the latter
cultures at each HA-1077 concentration (Figures 7B, 8B).
Discussion
Tumor cell migration is essential for metastasis, and me-
tastasis is the most common fatal complication of cancer
Figure 5 Inhibiting effect of HA-1077 on proliferation and RhoA activity and ROCK expression in UM-UC-3 cell using the
3-(4,5-dimethyl-2-thiazolyl)-2,5diphenyl-2H-tetrazolium (MTT) assay. The ratio of the cells treated with various doses (0.5–30 μM) of HA-1077
to control cells (HA-1077 0 μM) set as 1.0 were calculated. HA-1077 inhibited the growth of UM-UC-3 cell in a dose-dependent manner (A).
HA-1077 did not decrease the RhoA activity (B), but inhibited ROCK-I (C) and ROCK-II (D) in dose-dependent manner. The data show the 95%
confidential interval.
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tant organs to occur, migration of tumor cells through
the fluid spaces of the body is essential [7]. Y-27632 [18]
is another ROCK inhibitor that effectively suppresses
tumor cell motility [19,20]. We previously reported that
increased activity or overexpression of Rho and ROCK
were associated with local invasion, metastasis, and an
unfavorable prognosis of urogenital cancer including
urothelial cancer [21-23], indicating that the Rho/ROCK
pathway may be a potential target for anticancer therapy.
However, there has been no reliable data regarding the
effect on bladder cancer when ROCK is targeted by an
inhibitor.
In the present study, LPA and GGOH induced an in-
crease of cell proliferation that was correlated with in-
creases of both RhoA activity and ROCK expression.
The dose-dependent suppressive effect of HA-1077 on
cell proliferation was accompanied by a marked decreaseof ROCK-I and ROCK-II protein expression, while there
was only a slight decrease of RhoA activity. This inhibitory
effect of HA-1077 on cell proliferation was reduced by the
addition of LPA and GGOH to cultures. On the other
hand, RhoA activity was significantly higher in cultures
with HA-1077 plus LPA and GGOH at each HA-1077
concentration, but the difference in the level of ROCK-I
and ROCK-II protein expression between cultures with
HA-1077 alone and cultures with HA-1077 plus LPA and
GGOH gradually decreased at higher HA-1077 con-
centrations. These findings suggest that HA-1077 may
selectively inhibit urothelial tumor cell proliferation
via suppression of ROCK, but not by acting on RhoA.
The antiproliferative effect of HA-1077 was also evalu-
ated using the clonogenic assay. The clonogenic cell sur-
vival assay is an effective method for the determination
of single cell proliferation capacity, thereby retaining its
reproductive ability to form a large colony or a clone
Figure 6 The effects of HA-1077 (0.5–30 μM) on bladder cancer cell viability. Fluorescence images generated by terminal
deoxynucleotidyltransferase-mediated UTP end-labeling (TUNEL) analysis of the bladder cancer cells. Total cell population was visualized by
staining with 4′,6-diamidine-2-phenylin- dole (DAPI). Graph at right shows apoptotic index, the percentage of apoptotic cells in 1000 cells.
HA-1077 demonstrates apoptosis induction of 5637 (A) and UM-UC-3 cells (B). LPA plus GGOH reduced apoptotic cells in 5637 (C) and
UM-UC-3 cells (D). The data show the 95% confidential interval.
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able to form colonies in response to exposure to HA-1077
compared to those without any treatment. These results
suggested that HA-1077 inhibits the proliferation of blad-
der cancer cells at a certain rate.
With regard to apoptosis, HA-1077 caused the marked
induction of apoptosis in a dose-dependent manner, but
the difference in the percentage of apoptotic cells between
cultures with HA-1077 alone and cultures with HA-1077
plus LPA and GGOH gradually became smaller at higher
HA-1077 concentrations. This suggested that the pro-
apoptotic effect of HA-1077 was more effective suppres-
sion of ROCK at higher concentrations of HA-1077.
In the cell migration study, addition of LPA and
GGOH increased the migration of human bladder can-
cer cells. Cell migration was suppressed by HA-1077 in
a dose-dependent manner, while this suppressive effect
of HA-1077 was inhibited by addition of LPA and
GGOH. Western blotting analysis of the cells from theunderside of each filter showed that RhoA activity and
ROCK-I and ROCK-II expression were significantly
decreased by HA-1077 in a dose-dependent manner.
This dose-dependent inhibition of these proteins by
HA-1077 is likely to occur in parallel with a reduction
in the number of migrating cells, since RhoA activity
was higher in cultures with HA-1077 plus LPA and
GGOH at each HA-1077 concentration, while expression
of ROCK-I and ROCK-II did not increase.
LPA increases GTP loading, while GGOH activates
geranylgeranylation. The mevalonate pathway is required
for geranylgeranylation of Rho by GGOH. After Rho has
been activated by geranylgeranylation, its downstream
effector ROCK is activated when it selectively binds to
the active GTP-bound form of Rho. In the present study,
addition of LPA and GGOH to cultured cells increased
RhoA activity and up-regulated the expression of ROCK-I
and ROCK-II, while HA-1077 dramatically suppressed
both ROCK-I and ROCK-II dramatically, but did not
Figure 7 The effects of HA-1077 (0–30 μM) on migration in 5637 cell. The cancer cells were incubated in supplemented with HA-1077
with/without LPA and GGOH. (A) The percentage of migrated cells decreased in dose-dependent manner. LPA and GGOH blocked HA-1077
induced suppression of migration. (B-D) RhoA activity was not statistically different between with and without HA-1077, but ROCK-I and ROCK-II
expression was significantly reduced in the cells on the underside of each filter. The data show the 95% confidential interval.
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HA-1077 may selectively inhibit bladder cancer cell
proliferation and migration via suppression of ROCK,
but not by blocking RhoA activity.
It is important to study signaling cross-talk between
ROCK and other downstream effectors in the Rho family
of GTPases. ROCK belongs to the AGC (protein kinase
A/protein kinase G/protein kinase C) family of serine-
threonine kinases. ROCK-I and ROCK-II share 65%
overall identity, with 87% identity of the kinase domain
[11,36,37]. We previously reported that overexpression
of both ROCK-I and ROCK-II was associated with
poor differentiation, invasiveness, metastasis, and an
unfavorable prognosis of human bladder cancer [21].
In the present study, we found that the expression of
both ROCK-I and ROCK-II protein was decreased by
HA-1077. However, since HA-1077 and Y-27632 are
not highly selective for ROCK-I and ROCK-II, when
ROCK-I and ROCK-II were suppressed by HA-1077,downstream molecules such as the myosin binding
subunit of the myosin light chain (MLC) phosphatase
(MYPT)-1 and LIN-11, Isl1, and MEC-3 domain kinase
(LIMK) might compensate for ROCK inhibition [38].
Numerous downstream effectors are involved in the
Rho signaling pathway [39]. p140mDia is a mammalian
homologue of Drosophila diaphanous that controls actin
polymerization [40]. ROCK and p140mDia act coopera-
tively during stress fiber formation to mediate the effects
of Rho [41]. Arakawa et al. [42] showed that the direc-
tion of Rho signaling is dependent on the local level of
Rho-GTP, since a high Rho-GTP level induces ROCK
activation and a low level preferentially activates mDia
and induces Rac activation. Although we did not investi-
gate Rac, Cdc42, and mDia in the present study, Rac1
activity was increased in cancers of the human upper
urinary tract and was related to tumor progression in
our previous study [23]. Furthermore, HA-1077 did not
influence RhoA activity in the current study. Rho family
Figure 8 The effects of HA-1077 (0–30 μM) on migration in UM-UC-3 cell. The cancer cells were incubated in supplemented with HA-1077
with/without LPA and GGOH. (A) The percentage of migrated cells decreased in dose-dependent manner. LPA and GGOH blocked HA-1077
induced suppression of migration. (B-D) RhoA activity was not statistically different between with and without HA-1077, but ROCK-I and ROCK-II
expression was significantly reduced in the cells on the underside of each filter. The data show the 95% confidential interval.
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shown to differentially and cooperatively contribute to
triggering invasive behavior by tumor cells [43]. Taken
together, these findings suggest that if ROCK is sup-
pressed by a ROCK inhibitor, other signaling pathways
(including LIMK, Rho, Rac, Cdc42, and mDia) might be
activated to compensate for ROCK inhibition.
However, HA-1077 may still be an attractive candidate.
As described above, ROCK belongs to the AGC protein
kinase family of serine-threonine kinases [11,36,37], so
HA-1077 might have a nonspecific inhibitory effect on
other protein kinases from this family [44]. Mutation and/
or dysregulation of these AGC protein kinases contributes
to the pathogenesis of human cancer [45,46]. Recently,
Nakabayashi et al. reported that HA-1077 suppresses
neovascularization and tumor growth, in association
with reduced expression of VEGF, matrix metalloprotein-
ase (MMP)-2, and MMP-9, as well as attenuating the
phosphorylation of extracellular signal-regulated kinase 1and 2 (ERK1/2) and DNA binding activity of activator
proteins (a key downstream transcriptional factor for
ERK1/2) in malignant glioma cells, indicating that the
anti-angiogenic effect of HA-1077 may be due to the
combined inhibition of ROCK and the mitogen-activated
protein kinase kinase (MEK)/ERK pathway [47].
The Rho/ROCK pathway is known to play an important
role in the progression of cancer. The present findings
indicate that HA-1077 prevents the proliferation and
migration of bladder cancer cells and also induces apop-
tosis by inhibiting ROCK, suggesting that ROCK may be
an attractive molecular target agent for anticancer therapy.
However, this study did not show that HA-1077 was
equally effective in animal models of bladder cancer devel-
oped with the 5637 or UM-UC-3 bladder cancer cell lines.
Rath et al. suggested that a translational approach to
ROCK signaling is necessary for clinical development of
ROCK inhibitors to treat cancer and they identified the
following issues to be addressed: 1) the tissue and tumor
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ROCK inhibition, 3) the inhibition of ROCK targets and
parallel pathways, 4) the influence of combination therapy,
and 5) development of drugs targeting the extracellular
matrix of tumors [38]. In order to directly address these
issues, we should compare the effectiveness of HA-1077
and its vehicle control in vivo by developing a mouse
model of human bladder cancer in the future.
Improved understanding of how Rho family GTPases
and their downstream effectors mutually and specifically
interact in human cancers may throw more light on the
best therapeutic approach to cancer and might lead to
new treatment protocols.Conclusions
The Rho family of small GTP-binding proteins and its
best-characterized downstream effector, ROCK, are known
to have an important influence on the regulation of cell
motility and play a pivotal role in tumor progression. The
ROCK inhibitor HA-1077 effectively inhibits tumor cell
proliferation and migration and also induces apoptosis.
The present study investigated the effects of this ROCK
inhibitor on the growth, migration, and apoptosis of
bladder cancer cells. To explore the underlying molecu-
lar mechanisms, we treated bladder cancer cells with
HA-1077 and then examined changes of the GTP-bound
active form of RhoA and expression of its downstream ef-
fector ROCK. Treatment with HA-1077 caused a decrease
in the growth and migration of bladder cancer cells, while
apoptosis showed a significant increase. Expression of
ROCK-I and -II proteins was decreased by exposure of
tumor cells to HA-1077, while RhoA activity was not
affected. These findings indicate that HA-1077 prevents
the proliferation and migration of bladder cancer cells and
also induces apoptosis by inhibiting ROCK, suggesting
that ROCK may be a molecular target for the treatment of
cancer.
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